Medicare Enrolled
Dr. Linnea Chap, M.D.
Hematology & Oncology · Beverly Hills, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Chap from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Chap?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Chap
Dr. Linnea Chap is a hematology & oncology specialist in Beverly Hills, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Chap performed 8,711 Medicare services across 1,003 unique beneficiaries.
Between the years covered by Open Payments, Dr. Chap received a total of $671,753 from 91 pharmaceutical and/or device companies across 1444 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Chap is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 29% volume in CA
$671,753 industry payments
Medicare Practice Summary
Medicare Utilization ↗8,711
Medicare services
Top 29% in CA for hematology & oncology
1,003
Unique beneficiaries
$20
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~458 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Denosumab injection (Prolia/Xgeva) | 6,247 | $13 | $96 |
| Comprehensive metabolic blood panel A blood test that measures a group of chemicals, including glucose, electrolytes, and kidney and liver function markers. |
468 | $10 | $150 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
467 | $8 | $60 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 396 | $20 | $162 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
371 | $101 | $848 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
367 | $8 | $10 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
122 | $12 | $112 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
95 | $124 | $1,154 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
90 | $157 | $1,135 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
34 | $58 | $586 |
| Carcinoembryonic antigen (CEA) level test A blood test that measures the level of carcinoembryonic antigen (CEA) protein. This test is used to monitor certain types of cancer. |
25 | $19 | $147 |
| New patient office visit, complex (60-74 min) | 16 | $175 | $1,477 |
| Telephone medical discussion, 21-30 minutes A telephone conversation with a physician lasting between 21 and 30 minutes. This code covers the time spent discussing medical matters over the phone. |
13 | $78 | $1,000 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
1.1% high complexity
73.1% medium
25.8% routine
Industry Payment Transparency
Open Payments through 2024 ↗$671,753
Total received (2018-2024)
Avg $95,965/year across 7 years
Top 1% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
91
Companies
1,444
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$602,484 (89.7%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$49,146 (7.3%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$20,123 (3.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$160,887
2023
$170,436
2022
$117,610
2021
$55,330
2020
$30,447
2019
$86,108
2018
$50,935
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$65,533
PFIZER INC.
$63,522
Gilead Sciences, Inc.
$24,225
Eli Lilly and Company
$1,875
AstraZeneca UK Limited
$1,659
Merck Sharp & Dohme LLC
$1,431
Daiichi Sankyo Inc.
$921
Novartis Pharmaceuticals Corporation
$378
SUN PHARMACEUTICAL INDUSTRIES INC.
$178
Janssen Biotech, Inc.
$131
Menarini Silicon Biosystems, Inc.
$109
Incyte Corporation
$104
Bayer Healthcare Pharmaceuticals Inc.
$101
Lilly USA, LLC
$87
ABBVIE INC.
$83
BioNTech SE
$81
Takeda Pharmaceuticals U.S.A., Inc.
$76
Genmab U.S., Inc.
$62
Tempus AI, Inc
$48
SOBI, INC
$47
EMD Serono, Inc.
$36
Agios Pharmaceuticals, Inc.
$30
TerSera Therapeutics LLC
$26
Regeneron Healthcare Solutions, Inc.
$26
TAIHO ONCOLOGY, INC.
$26
Sumitomo Pharma America, Inc.
$23
Stemline Therapeutics Inc.
$21
Telix Pharmaceuticals
$20
Genentech USA, Inc.
$19
ARRAY BIOPHARMA INC
$5
Top 3 companies account for 95.3% of 2024 payments
All-time payments by company (2018-2024) ›
PFIZER INC.
$216,130
AstraZeneca Pharmaceuticals LP
$154,940
Seagen Inc.
$99,996
Genentech USA, Inc.
$61,892
Gilead Sciences, Inc.
$60,416
Novartis Pharmaceuticals Corporation
$21,999
Daiichi Sankyo Inc.
$18,803
NOVARTIS PHARMACEUTICALS CORPORATION
$7,293
PFIZER INTERNATIONAL LLC
$4,644
Eli Lilly and Company
$3,750
AstraZeneca UK Limited
$1,794
Immunomedics, Inc.
$1,750
Hologic Sales and Service, LLC
$1,582
Merck Sharp & Dohme LLC
$1,536
MACROGENICS, INC.
$1,500
Puma Biotechnology, Inc.
$1,144
Amgen Inc.
$907
Gen-Probe Sales & Service, Inc.
$829
Takeda Pharmaceuticals U.S.A., Inc.
$784
Bayer HealthCare Pharmaceuticals Inc.
$736
Janssen Biotech, Inc.
$595
Incyte Corporation
$548
Lilly USA, LLC
$532
Bayer Healthcare Pharmaceuticals Inc.
$435
Ipsen Biopharmaceuticals, Inc
$424
GE HealthCare
$342
Regeneron Healthcare Solutions, Inc.
$336
Merck Sharp & Dohme Corporation
$313
Foundation Medicine, Inc.
$306
Pharmacyclics LLC, An AbbVie Company
$297
EISAI INC.
$266
Eisai Inc.
$240
Astellas Pharma US Inc
$231
GENZYME CORPORATION
$225
Pharmacyclics LLC, an AbbVie Company
$223
TerSera Therapeutics LLC
$220
PUMA BIOTECHNOLOGY, INC.
$198
Celgene Corporation
$189
TESARO, Inc.
$184
SUN PHARMACEUTICAL INDUSTRIES INC.
$178
EMD Serono, Inc.
$172
Myriad Genetic Laboratories, Inc.
$144
Seattle Genetics, Inc.
$119
ADC Therapeutics America, Inc.
$118
Exelixis Inc.
$114
Blueprint Medicines Corporation
$110
Menarini Silicon Biosystems, Inc.
$109
ABBVIE INC.
$106
Stemline Therapeutics Inc.
$101
Teva Pharmaceuticals USA, Inc.
$100
MENARINI SILICON BIOSYSTEMS, INC.
$100
Clovis Oncology, Inc.
$100
Sun Pharmaceutical Industries Inc.
$84
BioNTech SE
$81
MorphoSys, US Inc.
$77
AVEO Pharmaceuticals, Inc.
$75
Myovant Sciences Inc.
$67
Karyopharm Therapeutics Inc.
$64
Genmab U.S., Inc.
$62
BeiGene USA, Inc.
$62
Roche Products Limited
$60
Acrotech Biopharma LLC
$60
Taiho Oncology, Inc.
$60
E.R. Squibb & Sons, L.L.C.
$57
TAIHO ONCOLOGY, INC.
$54
Tempus AI, Inc
$48
SOBI, INC
$47
Sumitomo Pharma America, Inc.
$46
CTI BioPharma Corp.
$45
GlaxoSmithKline, LLC.
$44
JAZZ PHARMACEUTICALS INC.
$42
Mirati Therapeutics, Inc.
$41
G1 Therapeutics, Inc.
$40
LEICA MICROSYSTEMS INC.
$40
Genentech, Inc.
$38
Kite Pharma, Inc.
$35
ARRAY BIOPHARMA INC
$31
Agios Pharmaceuticals, Inc.
$30
Alexion Pharmaceuticals, Inc.
$27
TOLMAR Pharmaceuticals, Inc.
$25
SANOFI-AVENTIS U.S. LLC
$24
Rigel Pharmaceuticals, Inc.
$23
AMAG Pharmaceuticals, Inc.
$23
Telix Pharmaceuticals
$20
TG THERAPEUTICS, INC.
$20
Global Blood Therapeutics, Inc.
$20
INSYS Therapeutics Inc
$19
Helsinn Therapeutics (U.S.), Inc.
$19
Dova Pharmaceuticals
$18
MEDIVATION FIELD SOLUTIONS LLC
$14
Heron Therapeutics, Inc.
$12
Top 3 companies account for 70.1% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · AKYNZEO · ALUNBRIG · APTIMA · AYVAKIT · Alecensa · Aranesp · Avastin · BAVENCIO · BELEODAQ · BENDEKA · BOSULIF · BRAC CDx · BRAFTOVI · BRILINTA · BRUKINSA · BTX · Balversa · Bavencio · Blincyto · CABOMETYX · CALQUENCE · CINVANTI · COSELA · Cabometyx · Cellsearch · Columvi · DARZALEX · DOPTELET · Doptelet · ELIGARD · ELITEK · ENHERTU · EPKINLY · EXKIVITY · Enhertu · Epkinly · Erleada · FASLODEX · FERAHEME · FETAL FIBRONECTIN ENZYME IMMUNOASSAY · FOLOTYN · FOTIVDA · FOUNDATIONONE · FRUZAQLA · GAVRETO · Halaven · Herceptin · IBRANCE · ILLUCCIX · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · Imbruvica · JADENU · JAKAFI · KEYTRUDA · KISQALI · KRAZATI · Kadcyla · Kyprolis · LIBTAYO · LIBTAYO CEMIPLIMAB-RWLC INJECTION · LONSURF · LORBRENA · LUMAKRAS · LYNPARZA · Lenvima · Lonsurf · MAMMOTOME · MARGENZA · MEKINIST · MONJUVI · NERLYNX · NINLARO · Nerlynx · Neulasta · Nexavar · Nplate · Nubeqa · OPDIVO · ORGOVYX · OXBRYTA · Orserdu · PADCEV · PEMAZYRE · PIQRAY · PLUVICTO · PROMACTA · PYRUKYND · Padcev · Perjeta · Phesgo · Pomalyst · Prolia · RYBREVANT · RYDAPT · Revlimid · Rezlidhia · Rubraca · SARCLISA · SOLIRIS · SOMATULINE DEPOT · SUTENT · SYNDROS · Somatuline Depot · Stivarga · TAGRISSO · TALZENNA · TASIGNA · TECENTRIQ · TRODELVY · TUKYSA · Tecentriq · Trodelvy · Truqap · UKONIQ · VARUBI · VELCADE · VENCLEXTA · VERZENIO · VONJO · Venclexta · Vitrakvi · Vonjo · XALKORI · XGEVA · XOSPATA · XPOVIO · XT CDX · XTANDI · Xermelo · Xospata · YONSA · Yescarta · ZEJULA · ZEPZELCA · ZOLADEX · ZYTIGA · Zoladex · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (90%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in hematology & oncology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 1% for hematology & oncology in CA.
Geographic Context
Hematology & oncology specialists within 10 mi
393
Per 100K population
4.0
County median income
$87,760
Nearest hospital
CEDARS-SINAI MEDICAL CENTER
0.8 mi
0.8 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Chap is a mixed practice specialist, with above-average Medicare volume (top 29% in CA), with speaking/promotional industry engagement in the top 1% of CA peers, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Chap experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Chap performed 6,247 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Chap receive payments from pharmaceutical companies?
Yes. Dr. Chap received a total of $671,753 from 91 companies across 1,444 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Chap's costs compare to other hematology & oncology specialists in Beverly Hills?
Dr. Chap's average Medicare payment per service is $20. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Chap) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Beverly Hills
Browse hematology & oncology specialists in Beverly Hills ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Seagen Inc. Payments to Doctors
See all physicians who received payments from Seagen Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology